Telehealth stock Hims & Hers (HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy. The ad criticized the ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site. The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. The ad ...

Hims & Hers Health (NYSE:HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels.

Hims & Hers (NYSE: HIMS) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the ...

As the MDGs era comes to a conclusion with the end of the year, 2016 ushers in the official launch of the bold and transformative 2030 Agenda for Sustainable Development adopted by world leaders ...

Several retirement tools are also available, including a retirement income calculator, expenses worksheets, and an inherited RMD calculator. Experienced investors who want access to fiduciary ...

Hims & Hers has capitalized on the outsize consumer demand for obesity drugs. (Hims & Hers Health) Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

Make data more insightful with free, online, collaborative spreadsheets. Microsoft Copilot in Excel unlocks the latest AI capabilities to help you achieve your goals—from creating a simple spreadsheet ...

8 more LGUs may declare outbreak At least eight more local government units in Metro ...